Literature DB >> 17088648

Replacement IgG therapy and self-therapy at home improve the health-related quality of life in patients with primary antibody deficiencies.

Ann Gardulf1, Uwe Nicolay.   

Abstract

PURPOSE OF REVIEW: This article describes the health-related quality of life and health of patients suffering from primary antibody deficiencies before and after the initiation of lifelong IgG replacement therapy, and before and after the introduction of home-therapy regime programmes. The importance of including patient-reported or parent-reported outcomes in evaluations of treatment and care of this group of patients is also discussed. RECENT
FINDINGS: Recently diagnosed adults suffering from primary antibody deficiencies and not yet on IgG therapy report poor health and poor health-related quality of life as compared with healthy individuals. Weekly subcutaneous IgG infusions (100 mg/kg) significantly improve health and normalize health-related quality of life. IgG self-infusions at home further improve the self-reported health and health-related quality of life of both adults and children. Being able to self-infuse at home instead of visiting the hospital two to four times per month has been shown to increase the treatment satisfaction of both adult patients and their families, and to result in increased flexibility, independence and sense of self-control.
SUMMARY: Adequate IgG replacement therapy means a dramatically improved life situation. Home-therapy programmes should be encouraged, as self-infusions at home further improve health-related quality of life and self-perceived health.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17088648     DOI: 10.1097/01.all.0000246619.49494.41

Source DB:  PubMed          Journal:  Curr Opin Allergy Clin Immunol        ISSN: 1473-6322


  36 in total

1.  Efficacy and safety of subcutaneous vivaglobin® replacement therapy in previously untreated patients with primary immunodeficiency: a prospective, multicenter study.

Authors:  Michael Borte; Isabella Quinti; Annarosa Soresina; Eduardo Fernández-Cruz; Bruce Ritchie; Dirk S Schmidt; Christine McCusker
Journal:  J Clin Immunol       Date:  2011-09-20       Impact factor: 8.317

2.  Immunoglobulin dosage and switch from intravenous to subcutaneous immunoglobulin replacement therapy in patients with primary hypogammaglobulinemia: decreasing dosage does not alter serum IgG levels.

Authors:  Sylvain Thépot; Marion Malphettes; Anaëlle Gardeur; Lionel Galicier; Bouchra Asli; Lionel Karlin; Laurence Gérard; Richard Laumont; Marie-Laure Doize; Bertrand Arnulf; Claire Fieschi; Djaouïda Bengoufa; Eric Oksenhendler
Journal:  J Clin Immunol       Date:  2010-07       Impact factor: 8.317

3.  International Consensus Document (ICON): Common Variable Immunodeficiency Disorders.

Authors:  Francisco A Bonilla; Isil Barlan; Helen Chapel; Beatriz T Costa-Carvalho; Charlotte Cunningham-Rundles; M Teresa de la Morena; Francisco J Espinosa-Rosales; Lennart Hammarström; Shigeaki Nonoyama; Isabella Quinti; John M Routes; Mimi L K Tang; Klaus Warnatz
Journal:  J Allergy Clin Immunol Pract       Date:  2015-11-07

4.  Subcutaneous immunoglobulin in lymphoproliferative disorders and rituximab-related secondary hypogammaglobulinemia: a single-center experience in 61 patients.

Authors:  Nicolò Compagno; Francesco Cinetto; Gianpietro Semenzato; Carlo Agostini
Journal:  Haematologica       Date:  2014-03-28       Impact factor: 9.941

5.  Health-related quality of life (HRQL) in immunodeficient adults with selective IgA deficiency compared with age- and gender-matched controls and identification of risk factors for poor HRQL.

Authors:  G H Jörgensen; A Gardulf; M I Sigurdsson; S Arnlaugsson; L Hammarström; B R Ludviksson
Journal:  Qual Life Res       Date:  2014-03       Impact factor: 4.147

6.  An immune globulin intravenous (human), 10% liquid privigen: for the treatment of primary immunodeficiency diseases.

Authors: 
Journal:  P T       Date:  2009-06

7.  Efficacy and tolerability of 16% subcutaneous immunoglobulin compared with 20% subcutaneous immunoglobulin in primary antibody deficiency.

Authors:  H B Niebur; C M Duff; G F Shear; D Nguyen; T K Alberdi; M J Dorsey; J W Sleasman
Journal:  Clin Exp Immunol       Date:  2015-07-07       Impact factor: 4.330

8.  Rapid subcutaneous immunoglobulin administration every second week results in high and stable serum immunoglobulin G levels in patients with primary antibody deficiencies.

Authors:  R Gustafson; A Gardulf; S Hansen; H Leibl; W Engl; M Lindén; A Müller; L Hammarström
Journal:  Clin Exp Immunol       Date:  2008-03-12       Impact factor: 4.330

9.  Subcutaneous immunoglobulin replacement therapy in the treatment of patients with primary immunodeficiency disease.

Authors:  Suzanne Skoda-Smith; Troy R Torgerson; Hans D Ochs
Journal:  Ther Clin Risk Manag       Date:  2010-02-02       Impact factor: 2.423

10.  Efficacy and safety of a new 20% immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with primary immunodeficiency.

Authors:  John B Hagan; Mary B Fasano; Sheldon Spector; Richard L Wasserman; Isaac Melamed; Mikhail A Rojavin; Othmar Zenker; Jordan S Orange
Journal:  J Clin Immunol       Date:  2010-05-08       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.